The RXR agonist LG100268 causes hepatomegaly, improves glycaemic control and decreases cardiovascular risk and cachexia in diabetic mice suffering from pancreatic beta-cell dysfunction.

J M Lenhard; M E Lancaster; M A Paulik; J E Weiel; J G Binz; S S Sundseth; B A Gaskill; R M Lightfoot; H R Brown

doi:10.1007/s001250051193

The RXR agonist LG100268 causes hepatomegaly, improves glycaemic control and decreases cardiovascular risk and cachexia in diabetic mice suffering from pancreatic beta-cell dysfunction.

Identifier:nobleid.org/w1/20260515/D50DEEE2

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/D50DEEE2.svg?ark=w1%2F20260515%2FD50DEEE2)](https://nobleid.org/work/w1/20260515/D50DEEE2)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

The RXR agonist LG100268 causes hepatomegaly, improves glycaemic control and decreases cardiovascular risk and cachexia in diabetic mice suffering from pancreatic beta-cell dysfunction.

Identifier:nobleid.org/w1/20260515/D50DEEE2

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/D50DEEE2.svg?ark=w1%2F20260515%2FD50DEEE2)](https://nobleid.org/work/w1/20260515/D50DEEE2)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work